Age-dependent therapeutic effects of once-daily molsidomine used as an add-on treatment in patients with stable angina pectoris

HeartDrug

Volumn 4, Issue 4, 2004, Pages 184-189

  Messin, Roger ^a   Carreer Bruhwyler, Fabienne ^b   Dubois, Claude ^a   Famaey, Jean Pierre ^a   Géczy, Joseph ^a  

^a Therabel Pharma Belgium   (Belgium)

^b Squarepoint Pointcarre SPRL   (Belgium)

Author keywords

Elderly patients; Molsidomine; Once daily treatment; Quality of life; Stable angina pectoris

Indexed keywords

CORUNO; CORVATARD; MOLSIDOMINE; NITROGEN DERIVATIVE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; FREQUENCY ANALYZER; HEART RATE; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MATRIX TABLET; PATIENT SELECTION; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RECORDING; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYMPTOM; VALIDATION PROCESS;

EID: 11444254090     PISSN: 14229528     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082189     Document Type: Article

References (10)

1. Rosenkranz B, Winkelmann BR, Parnham MJ: Clinical pharmacokinetics of molsidomine. Clin Pharmacokinet 1996;30:372-384.
2. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84:9265-9269.
3. Kirsten R, Nelson K, Kirsten D, Heintz B: Clinical pharmacokinetics of vasodilators. Part II. Clin Pharmacokinet 1998;35:9-36.
4. Messin R, Boxho G, De Smedt J, Buntinx IM: Acute and chronic effect of molsidomine extended release on exercise capacity in patients with stable angina pectoris, a double-blind cross-over clinical trial versus placebo. J Cardiovasc Pharmacol 1995;25:558-563.
5. Messin R, Karpov Y, Baikova N, Bruhwyler J, Monseu MJ, Guns C, Géczy J: Short- and longterm effects of molsidomine retard and molsidomine nonretard on exercise capacity and clinical status in patients with stable angina: A multicenter randomized double-blind crossover placebo-controlled trial. J Cardiovasc Pharmacol 1998;31:271-276.
6. Herchuelz A, Carreer-Bruhwyler F, Crommen J, Chiap P, Hubert P, Messin R, Dubois C, Famaey JP, Géczy J: Clinical pharmacokinetics of molsidomine: From immediate-release to prolonged-release once-a-day formulations. Am J Drug Deliv, in press.
7. Messin R, Fenyvesi T, Carreer-Bruhwyler F, Crommen J, Chiap P, Hubert P, Dubois C, Famaey JP, Géczy J: A pilot double-blind randomized placebo-controlled study of molsidomine 16 mg once-a-day in patients suffering from stable angina pectoris: Correlation between efficacy and over time plasma concentrations. Eur J Clin Pharmacol 2003;59:227-232.
8. Zwinderman AH, Cleophas TJ, Niemeyer MG, Van Der Wall EE, on behalf of the Dutch Mononitrate Quality of Life (DUMQOL) Study Group: Comparison of 50-mg and 100-mg sustained-release isosorbide mononitrate in the treatment of stable angina pectoris: Effects on quality-of-life indices. Curr Ther Res 1998;59:511-519.
9. Feinstein A, Fisher M, Pigeon J: Changes in dyspnea-fatigue ratings as indicators of quality of life in the treatment of congestive heart failure. Am J Cardiol 1989;64:50-55.
10. Kumar S, Hall R: Drug treatment of stable angina pectoris in the elderly: Defining the place of calcium channel antagonists. Drugs Aging 2003;20:805-815.